Shares of Curis, Inc. (NASDAQ:CRIS) traded down 5.1% during mid-day trading on Friday . The company traded as low as $0.56 and last traded at $0.56. 538,997 shares traded hands during trading, a decline of 74% from the average session volume of 2,088,339 shares. The stock had previously closed at $0.59.
Separately, Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $7.00.
The company has a debt-to-equity ratio of 1.49, a quick ratio of 4.56 and a current ratio of 4.56.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.04. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. The company had revenue of $3.26 million for the quarter, compared to analyst estimates of $2.03 million. During the same period in the prior year, the firm earned ($0.08) earnings per share. equities analysts predict that Curis, Inc. will post -0.38 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its stake in shares of Curis by 1,341.7% during the fourth quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock worth $2,204,000 after buying an additional 2,930,725 shares during the period. Two Sigma Investments LP increased its stake in shares of Curis by 1,816.6% during the fourth quarter. Two Sigma Investments LP now owns 854,944 shares of the biotechnology company’s stock worth $598,000 after buying an additional 810,336 shares during the period. Two Sigma Advisers LP increased its stake in shares of Curis by 1,591.5% during the fourth quarter. Two Sigma Advisers LP now owns 331,922 shares of the biotechnology company’s stock worth $232,000 after buying an additional 312,299 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Curis by 136.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 504,371 shares of the biotechnology company’s stock worth $353,000 after buying an additional 290,812 shares during the period. Finally, Thrivent Financial For Lutherans purchased a new stake in shares of Curis during the fourth quarter worth approximately $108,000. Hedge funds and other institutional investors own 47.66% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Curis (CRIS) Shares Down 5.1%” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/22/curis-cris-shares-down-5-1.html.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.